What Is the Risk for Mortality After Diagnosis of Melanoma in Situ?

Researchers find 15-year relative survival to be 112.4 percent and all-cause standardized mortality ratio to be 0.68

By Dermsquared Editorial Team | June 07, 2023

WEDNESDAY, June 7, 2023 -- Patients with melanoma in situ (MIS) have higher relative survival and lower all-cause mortality than the general population, according to a study published online June 7 in JAMA Dermatology.

Vishal R. Patel, from Dell Medical School at the University of Texas at Austin, and colleagues examined mortality and factors associated with mortality after a diagnosis of MIS in a population-based cohort study. Data were included for 137,872 patients with a first and only MIS (mean age at diagnosis, 61.9 years); mean follow-up was 6.6 years.

The researchers found that the 15-year melanoma-specific survival was 98.4 percent and the 15-year relative survival was 112.4 percent. Patients with MIS had a melanoma-specific standardized mortality ratio (SMR) of 1.89, while all-cause SMR was 0.68. Older patients had a higher risk for melanoma-specific mortality (7.4 percent for those aged 80 years and older versus 1.4 percent for those aged 60 to 69 years; hazard ratio, 8.2), as did those with acral lentiginous histology results (3.3 percent for acral lentiginous versus 0.9 percent for superficial spreading; hazard ratio, 5.3). Overall, 4.3 percent of those with primary MIS experienced a second primary invasive melanoma and 7.4 percent experienced a second primary MIS. The risk for melanoma-specific mortality was increased for those with a second primary invasive melanoma and was reduced for those with a second primary MIS compared with those without subsequent melanoma (adjusted hazard ratios, 4.1 and 0.7, respectively).

"Patients with a diagnosis of MIS have an increased but low risk of melanoma-specific mortality and live longer than people in the general population, suggesting significant detection of low-risk disease among health-seeking individuals," the authors write.

One author disclosed ties to Concert Genetics.


The leading platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved